Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $137.9 million.

  • Avidity Biosciences' Shares Outstanding (Weighted Average) rose 1176.9% to $137.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.9 million, marking a year-over-year increase of 1176.9%. This contributed to the annual value of $111.6 million for FY2024, which is 5282.69% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Shares Outstanding (Weighted Average) is $137.9 million, which was up 1176.9% from $129.6 million recorded in Q2 2025.
  • Avidity Biosciences' Shares Outstanding (Weighted Average)'s 5-year high stood at $137.9 million during Q3 2025, with a 5-year trough of $37.5 million in Q1 2021.
  • In the last 5 years, Avidity Biosciences' Shares Outstanding (Weighted Average) had a median value of $71.4 million in 2023 and averaged $77.8 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first surged by 121884.01% in 2021, then soared by 1176.9% in 2025.
  • Quarter analysis of 5 years shows Avidity Biosciences' Shares Outstanding (Weighted Average) stood at $41.4 million in 2021, then grew by 25.91% to $52.2 million in 2022, then surged by 39.97% to $73.0 million in 2023, then skyrocketed by 52.83% to $111.6 million in 2024, then increased by 23.58% to $137.9 million in 2025.
  • Its last three reported values are $137.9 million in Q3 2025, $129.6 million for Q2 2025, and $129.2 million during Q1 2025.